Molnupiravir and Favipiravir in the therapeutics of SARS-CoV-2 - A review

Abstract

SARS-CoV-2 led to several unwanted deaths all across the globe since 2020. High mortality rates are seen by this virus. As per the various theories, numerous variant and deadly strains are come into existence in the world due to COVID-19 pandemic. To treat deadly strains of this virus, various anti-viral are drugs that are utilized in the therapeutics of COVID-19. Few antivirals are molnupiravir, favipiravir, remdesivir, alisopirivir and many more. Molnupiravir was originally developed to treat influenza at Emory University but also reports abandoned for mutagenicity concerns. Favipiravir is a prodrug has been approved to treat the influenza rather than the seasonal influenza and this medication selectively inhibition of RdRp. This review generally covers the two potent oral antiviral molnupiravir and favipiravir investigation.